Related Experiment Video
Updated: Jul 13, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Angiogenesis as targeted breast cancer therapy
Daniel F Hayes1, Kathy Miller, George Sledge
1Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 CCGC, Ann Arbor, MI 48109, USA. hayesdf@umich.edu
Breast (Edinburgh, Scotland)
|August 21, 2007
Summary
Inhibiting tumor angiogenesis, the growth of new blood vessels, is a promising cancer treatment strategy. Bevacizumab, targeting vascular endothelial growth factor (VEGF), shows efficacy in various cancers, including colorectal and metastatic breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Neo-angiogenesis is crucial for tumor growth, migration, and metastasis.
- Inhibiting angiogenesis presents a viable strategy for cancer treatment.
- Tumor vascularization is regulated by numerous pro- and anti-angiogenic factors.
Purpose of the Study:
- To review the role of anti-angiogenic agents in cancer therapy.
- To highlight the efficacy of bevacizumab in treating various malignancies.
- To discuss emerging anti-angiogenic therapies and their potential.
Main Methods:
- Review of clinical trial data and scientific literature on angiogenesis inhibitors.
- Focus on bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF).
- Exploration of other anti-angiogenic agents, including small molecule inhibitors.
Main Results:
- Bevacizumab demonstrates significant activity in malignancies like colorectal cancer.
- A clinical trial showed improved response rates and progression time for metastatic breast cancer when treated with paclitaxel plus bevacizumab.
- Ongoing research is evaluating bevacizumab in combination with other agents and in earlier disease settings.
Conclusions:
- Anti-angiogenic therapy, particularly with bevacizumab, is becoming an integral part of medical oncology.
- Bevacizumab offers a promising approach for treating various cancers, with ongoing investigations into its broader applications.
- Small molecule inhibitors targeting VEGF receptor tyrosine kinase activity also show potential.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...